| Inhibitory Mechanism | Classification | Antibiotic(s) | Spectrum Notes | Primary Systems | General Notes | Adult Dose (Germany / typical) | My Tips / Recommendations |
|---|---|---|---|---|---|---|---|
| Cell Wall (β-lactam) | Natural Penicillins | **Penicillin G** | Gram+ (Strep, Enterococcus), Neisseria, Treponema. No β-lactamase staph. Anaerobes + (mouth). | Resp, Skin, Multi | IV only. First line for neurosyphilis, endocarditis with Strep viridans. Allergy risk high. Safe in pregnancy. | 4–5 Mio IE IV q4h for severe Strep, endocarditis. Neurosyphilis: 18–24 Mio IE/day continuous IV. | Think: Syphilis = Pen G. If MSSA, do not use Pen G. If allergic, document clearly because this blocks many first-line options. |
| Cell Wall (β-lactam) | Natural Penicillins | **Penicillin V** | Narrow Gram+. Good for Streptococcus pyogenes (Tonsillitis, Scharlach). | Resp | PO only. Less GI than amoxicillin. | 1–1.5 Mio IE PO q6h for Strep pharyngitis. | Use for Streptococcus tonsillitis if narrow is enough. Keeps pressure off amoxicillin and macrolides. |
| Cell Wall (β-lactam) | Antistaphylococcal Penicillins | **Flucloxacillin** | MSSA, Streptococci. No MRSA. No Gram−. | Skin, Bone, Endocarditis | IV/PO. First-line for MSSA in Germany. Good bone penetration. Hepatic cholestasis risk. | 2 g IV q6h for severe MSSA bacteremia. PO 1 g q6h mild SSTI. | Very important. In MSSA bacteremia, switch from vancomycin to flucloxacillin as soon as you know MSSA, mortality benefit. |
| Cell Wall (β-lactam) | Aminopenicillins | **Amoxicillin** | Gram+ (Strep, Enterococcus, Listeria), some Gram− (H. influenzae, E. coli), no β-lactamase staph. | Resp, ENT, UTI | PO first-line for Otitis media, Sinusitis, Bronchitis with bacterial suspicion. Rash with EBV. | 1 g PO TID (every 8 h) for sinusitis, otitis, CAP (non-severe). | First choice ambulatory. If risk of β-lactamase, go Amoxi-Clav. Avoid in suspected EBV (generalized rash, not allergy). |
| Cell Wall (β-lactam) | Broad-spectrum Penicillins + β-lactamase inhibitor | **Piperacillin/Tazobactam** | Broad Gram− incl. Pseudomonas, Gram+, anaerobes. No MRSA. | GI, Resp, UTI, Sepsis | IV only. Empiric for severe sepsis, intraabdominal abscess, neutropenic fever. Renal adjust. High Na load. | 4.5 g IV q6–8h (extended infusion common). | In sepsis algorithm in German hospitals. If severe sepsis with shock and unknown focus, “Pip/Tazo + Vanco” is common start. Mention Pseudomonas coverage. |
| Cell Wall (β-lactam) | 3rd Gen Cephalosporins | **Ceftriaxone** | Strong Gram− incl. Enterobacterales, Neisseria. Good Strep (incl. S. pneumoniae). No Pseudomonas. No MRSA. Good CNS penetration. | Resp, CNS, UTI, Sepsis | IV/IM. Biliary excretion. No renal adjust usually. Avoid in neonates (kernicterus, Ca-precipitation). | 2 g IV q24h for pneumonia, pyelonephritis, sepsis. Meningitis: 2 g IV q12h. | Extremely common on internal medicine wards in Germany. If suspected meningitis: Ceftriaxone + Ampicillin (Listeria) + Vanco (resistant pneumococcus). |
| Cell Wall (β-lactam) | Carbapenems | **Meropenem** | Ultra broad. Gram+, Gram− incl. Pseudomonas, anaerobes. ESBL. | GI, Sepsis, CNS | IV only. Lower seizure risk than imipenem. Covers most abdominal sepsis. | 1 g IV q8h (extended infusion in ICU). Meningitis 2 g IV q8h. | Go-to for ESBL sepsis in German ICU. Say “Carbapenem for ESBL” in exam. |
| Cell Wall (non-β-lactam) | Glycopeptides | **Vancomycin** | Gram+ only. MRSA, MRSE, Enterococci (not all VRE), Strep. No Gram−. | Skin, Resp, Sepsis, CNS | IV for systemic. PO only for C. difficile. Therapeutic drug monitoring needed. Nephrotoxic and ototoxic. | Load 25–30 mg/kg IV once, then ~15 mg/kg IV q12h. PO 125 mg q6h for C. diff. | Gold standard for MRSA bacteremia and MRSA pneumonia initial therapy. Say “monitor trough 15–20 mg/L in serious infections”. |
| Cell Wall (non-β-lactam) | Glycopeptides | **Teicoplanin** | Similar to vancomycin vs Gram+. Long half-life. | Skin, Sepsis | IV/IM. Often used in Europe instead of Vanco due to easier dosing and less nephrotoxicity. | Loading 6–12 mg/kg IV q12h x3 doses, then q24h. | In Germany, many centers prefer Teicoplanin for MRSA if MIC low. Mention long half-life and once-daily maintenance. |
| Protein Synthesis 30S | Tetracyclines | **Doxycycline** | Broad. Gram+ incl. CA-MRSA, atypicals (Chlamydia, Mycoplasma), Rickettsia, Borrelia. Some Gram− (respiratory). | Resp, Skin, Multi | PO/IV. Photosensitivity. Avoid in pregnancy and in children under 8. Good lung penetration. | 100 mg PO/IV q12h. | Outpatient CAP with atypical suspicion. Tick diseases. Acne. MRSA skin abscess oral option if mild. |
| Protein Synthesis 50S | Macrolides | **Azithromycin** | Atypicals (Legionella, Chlamydia), Strep pneumo (but resistance rising), H. influenzae. | Resp, STI | PO/IV. Long half-life. Low CYP interactions vs clarithro. QT prolongation risk. | CAP: 500 mg PO day 1, then 250 mg PO daily days 2–5. Chlamydia: 1 g PO single dose. | In CAP on ward, “Ceftriaxone + Azithro” = classic combo for typical + atypical. Also first-line for Chlamydia urethritis (single dose). |
| Protein Synthesis 50S | Oxazolidinones | **Linezolid** | Gram+ only. MRSA, VRE, penicillin-resistant pneumococcus. | Resp, Skin, Sepsis | IV/PO 100 percent bioavailability. Bone marrow suppression if >14 days. Risk serotonin syndrome with SSRIs. | 600 mg IV/PO q12h. | If MRSA pneumonia and vancomycin MIC high, switch to Linezolid. Also oral option for VRE. Mention thrombocytopenia monitoring. |
| DNA damage (anaerobe activation) | Nitroimidazoles | **Metronidazole** | Anaerobes (Bacteroides, Clostridioides), Gardnerella, Trichomonas, Giardia, Entamoeba. No aerobes. | GI, CNS | IV/PO. Full anaerobic coverage below diaphragm. Disulfiram-like with alcohol. Metallic taste. | 500 mg IV/PO q8h for intraabdominal / brain abscess. Single 2 g PO for Trichomonas. | Saying “Metronidazole covers anaerobes below the diaphragm” is an exam classic. Also first-line for bacterial vaginosis and for C. diff if no fidaxomicin/vancomycin available. |
| DNA damage in urine | Nitrofurans | **Nitrofurantoin** | E. coli, Enterococcus, Staph saprophyticus in bladder. No Pseudomonas, no Proteus. | UTI (cystitis only) | PO only. High urine levels, low serum. Contraindicated if CrCl <30. Avoid near term pregnancy. Causes rare pulmonary fibrosis with long-term use. | 100 mg PO BID for 5 days (retard formulation). | First-line for uncomplicated cystitis in Germany. Do NOT use for pyelonephritis because it does not reach kidney parenchyma. |
| Cell Wall (other) | Phosphonic acid derivative | **Fosfomycin** | Broad incl. ESBL E. coli, Enterococcus (even VRE sometimes), some MRSA. High urine levels. | UTI | PO single-dose for uncomplicated cystitis. IV form used in combo for MDR sepsis. | PO 3 g single dose once. IV 4–8 g IV q8h in severe infections (renal adjust). | In Germany first-line for uncomplicated cystitis in women. Say this. Important for exam. |
| RNA synthesis (C. difficile specific) | Fidaxomicin | Fidaxomicin | Narrow: C. difficile. Kills C. diff with minimal effect on normal flora. | GI | PO only. First-line for C. difficile colitis in many German hospitals. Expensive but fewer relapses than metronidazole. | 200 mg PO BID x10 days. | KP question: “Therapie der Clostridioides-difficile-Kolitis?” Answer now = Fidaxomicin first choice, then oral Vancomycin. |
